SCHEMBL15041818

SCHEMBL15041818

CN(C)C(=O)c1cc2cnc(Nc3ccc(NC4CCNCC4)cc3)nc2n(C2COc3ccccc3C2=O)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 19/20 0.45
CCND1 P24385 8/20 0.45
CDK2 P24941 5/20 0.43
FGFR1 P11362 3/20 0.43
CCNA2 P20248 3/20 0.43
FGFR2 P21802 3/20 0.43
FGFR4 P22455 3/20 0.43
FGFR3 P22607 3/20 0.43
CCND3 P30281 12/20 0.40
CCNE1 P24864 1/20 0.40
CDK6 Q00534 1/20 0.40
CDK9 P50750 2/20 0.40
CDK1 P06493 1/20 0.40
HDAC1 Q13547 4/20 0.39
AURKA O14965 1/20 0.39
CCNT1 O60563 1/20 0.39
NTRK1 P04629 1/20 0.39
FLT4 P35916 1/20 0.39
LIMK1 P53667 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035438 0.92 CDK4 (0.41) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15035385 0.78 JAK2 (0.45) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15041844 0.78 CDK4 (0.47) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15041318 0.76 CDK4 (0.44) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15041291 0.75 CDK4 (0.44) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15041612 0.74 CDK4 (0.43) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15041801 0.73 CDK4 (0.42) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15041565 0.73 CAMK2D (0.41) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15041596 0.71 CDK4 (0.40) CDK4CCND1CDK2FGFR1CCNA2
SCHEMBL15035313 0.71 CDK4 (0.39) CDK4CCND1CDK2FGFR1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CCND1 2153/4885CDK2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.